Key Performance
More- Earnings Score: 85
- Momentum Score: 49
- True Yield: N/A
- Financial Health Score: 60
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
The global telehealth market is experiencing significant growth, projected to expand from $77.4 billion in 2025 to $187.5 billion by 2033. Key developments include AI-powered diagnostics, remote patient monitoring, and virtual care expansion. Rocket Doctor AI joined the Altais network to expand telehealth services in California, while competitors like Teladoc Health, Amwell, Hims & Hers, and Doximity launched new AI capabilities and research initiatives to enhance digital healthcare delivery.
11/11/2026, 9:00 AM • GlobeNewswire
Hims & Hers Health vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy for 2027?
The article compares two healthcare disruptors: Hims & Hers Health, a high-growth telehealth platform with 59% revenue growth but facing regulatory scrutiny, and Intuitive Surgical, a dominant medical robotics leader with strong profitability and a 12% increase in installed systems. While both stocks declined in 2026, the author recommends Intuitive Surgical for its stronger competitive moat and market position, despite both being considered speculative investments.
11/06/2026, 10:05 PM • The Motley Fool
A securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. for material misstatements regarding deceptive privacy practices. The FTC accused HIMS of sharing customers' medical information with third-party advertisers including Meta and Snap. Following the FTC lawsuit announcement on July 29, 2026, HIMS stock declined 14.73%. Investors have until November 2, 2026, to file for lead plaintiff status.
11/01/2026, 11:46 AM • GlobeNewswire
The Rosen Law Firm is reminding investors in Hims & Hers Health, Inc. of the November 2, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Hims made false statements regarding consumer data sharing with third-party advertising platforms, improper billing practices, and regulatory exposure, resulting in investor losses.
11/01/2026, 1:05 AM • GlobeNewswire
Rosen Law Firm is reminding investors in Doximity, Inc., Hims & Hers Health, Inc., and Honeywell Aerospace Inc. of upcoming deadlines to join securities class action lawsuits. Investors with losses exceeding $100K are encouraged to secure counsel before the respective deadlines. The lawsuits allege that these companies made misleading statements regarding their business performance and market position.
10/31/2026, 9:49 PM • GlobeNewswire
Rosen Law Firm is reminding investors in Hims & Hers Health, Doximity, and Honeywell Aerospace of upcoming lead plaintiff deadlines in securities class action lawsuits. The HIMS lawsuit alleges the company made false statements regarding data privacy practices and prescription charging procedures. Investors with losses exceeding $100K are encouraged to secure counsel before the November 2, 2026 deadline.
10/31/2026, 9:02 PM • GlobeNewswire
A class action lawsuit has been filed against Hims & Hers Health, Inc. alleging securities fraud. The complaint claims the company made false statements about consumer privacy, misrepresented billing practices, and failed to disclose regulatory risks. Investors who purchased Hims securities between August 4, 2025 and July 29, 2026 are encouraged to join the case.
10/29/2026, 11:00 PM • GlobeNewswire
Hims & Hers Health faces a securities class action lawsuit following an FTC complaint alleging deceptive health data sharing with third-party advertising platforms and ROSCA violations related to subscription billing practices. The company's stock plunged 14.7% on July 29, 2026, erasing over $970 million in market value. Investors with substantial losses are urged to submit claims before the November 2, 2026 deadline.
10/28/2026, 5:56 PM • GlobeNewswire
A class action lawsuit has been filed against Hims & Hers Health, Inc. alleging securities fraud. The complaint claims the company made false statements about sharing consumer health data with third-party advertisers, charged for prescriptions immediately despite promising consultations, and failed to disclose regulatory risks and potential penalties. Investors who purchased Hims securities between August 4, 2025 and July 29, 2026 may be eligible to join the case.
10/26/2026, 11:00 PM • GlobeNewswire
Rosen Law Firm has filed securities class action lawsuits against Innventure, Inc., Flotek Industries, Inc., and Hims & Hers Health, Inc., alleging materially false and misleading statements. Innventure is accused of overstating revenue targets related to Accelsius Holdings' deal with DarkNX. Investors have until specified deadlines in late October and early November 2026 to join the class actions.
10/25/2026, 7:14 PM • GlobeNewswire
Rosen Law Firm issued deadline notices for securities class action lawsuits against Flotek Industries (FTK), Innventure Inc. (INV), and Hims & Hers Health (HIMS). The lawsuits allege materially false and misleading statements regarding business operations and financial prospects. Lead plaintiff deadlines range from October 26 to November 2, 2026.
10/25/2026, 7:09 PM • GlobeNewswire
A securities class action lawsuit has been filed against Hims & Hers Health, Inc. alleging the company made materially false statements regarding consumer health data sharing with third-party advertisers, premature prescription charges despite promised consultations, and undisclosed regulatory scrutiny. Investors who purchased HIMS securities between August 4, 2025 and July 29, 2026 may be eligible for compensation. The lead plaintiff deadline is November 2, 2026.
10/25/2026, 6:45 PM • GlobeNewswire
Hims & Hers Health faces a securities class action lawsuit following an FTC federal complaint alleging deceptive health data sharing with third-party advertising platforms and ROSCA violations related to subscription billing practices. The allegations caused HIMS stock to plunge $4.32 (-14.7%) on July 29, 2026, erasing over $970 million in market capitalization. Investors with losses are encouraged to contact Hagens Berman before the November 2, 2026 lead plaintiff deadline.
10/25/2026, 2:21 PM • GlobeNewswire
Multiple securities class action lawsuits have been filed against several companies including Millrose Properties, Gildan Activewear, J.B. Hunt Transport Services, Beta Bionics, Hims & Hers Health, and Flotek Industries. Investors who purchased securities during specified class periods are encouraged to contact legal counsel before upcoming lead plaintiff deadlines. The lawsuits allege material misrepresentations and non-disclosures regarding business operations and financial performance.
10/25/2026, 2:05 PM • GlobeNewswire
A class action lawsuit has been filed against Hims & Hers Health, Inc. alleging securities fraud. The complaint claims the company made materially false statements regarding consumer health data sharing with third-party advertisers, premature prescription charges despite promises of provider consultation, and failed to disclose regulatory scrutiny and potential penalties. Investors who purchased Hims securities between August 4, 2025 and July 29, 2026 are eligible to join the case.
10/22/2026, 11:00 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 11/10/2026
Company Profile
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. The company was formerly known as Hims, Inc. and changed its name to Hims & Hers Health, Inc. in January 2021. The company was founded in 2017 and is based in San Francisco, California.